array:19 [
  "pii" => "X0211699504030713"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2004-12-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2004;24 Supl 6:5-9"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 4433
    "formatos" => array:3 [
      "EPUB" => 298
      "HTML" => 3410
      "PDF" => 725
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699504030705"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-12-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 6:10-1"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4487
      "formatos" => array:3 [
        "EPUB" => 309
        "HTML" => 3593
        "PDF" => 585
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Indice de figuras y algoritmos"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "10"
          "paginaFinal" => "11"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Sociedad Española de Nefrología"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "Sociedad Española de Nefrología"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504030705?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S6/v0_201502091332/X0211699504030705/v0_201502091332/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699504030721"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-12-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 6:0"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3814
      "formatos" => array:3 [
        "EPUB" => 283
        "HTML" => 2777
        "PDF" => 754
      ]
    ]
    "es" => array:9 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Indice General</span>"
      "titulo" => "Indice General"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "0"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504030721?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S6/v0_201502091332/X0211699504030721/v0_201502091332/es/main.assets"
  ]
  "es" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Indice de tablas"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "5"
        "paginaFinal" => "9"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOG&#205;A&#46; Volumen 24&#46; Suplemento N&#186; 6 &#183; 2004 &#205;ndice de tablas Tabla 1&#46; Tabla 2&#46; Tabla 3&#46; Tabla 4&#46; Tabla 5&#46; Tabla 6&#46; Tabla 7&#46; Tabla 8&#46; Tabla 9&#46; Definici&#243;n de los niveles de evidencia &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 19 Principales mecanismos hipertensivos de origen renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 22 Factores implicados en el desarrollo de la aterosclerosis en los pacientes con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 23 Clasificaci&#243;n de los estadios de la enfermedad renal cr&#243;nica &#40;ERC&#41; seg&#250;n las gu&#237;as de la National Kidney Foundation &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 27 Plan de actuaci&#243;n en los distintos estadios de enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 28 Objetivos principales de las gu&#237;as de la National Kidney Foundation &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 30 Situaciones consideradas como da&#241;o renal para el diagn&#243;stico de enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 30 Prevalencia de enfermedad renal cr&#243;nica en la poblaci&#243;n no institucionalizada mayor de 20 a&#241;os en Estados Unidos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 31 Prevalencia de las distintas categor&#237;as de funci&#243;n renal seg&#250;n el m&#233;todo utilizado y por grupos de edad en la poblaci&#243;n no institucionalizada mayor de 20 a&#241;os en Estados Unidos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 31 Datos principales de los estudios sobre prevalencia de enfermedad renal cr&#243;nica en Espa&#241;a &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 32 Situaciones de riesgo aumentado de enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 33 Factores de riesgo para la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 33 Principales ecuaciones para la medida de la funci&#243;n renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 36 Medidas &#34;ideales&#34; de funci&#243;n renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 37 Problemas de la determinaci&#243;n de creatinina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 37 Problemas de la determinaci&#243;n del aclaramiento de creatinina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 39 Ecuaciones recomendadas para estimar la funci&#243;n renal en pacientes en situaci&#243;n estable &#46; &#46; &#46; 39 Estudios comparativos entre las ecuaciones MDRD y Cockcroft-Gault &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 40 Situaciones en las que no se recomienda la utilizaci&#243;n de ecuaciones para medir la funci&#243;n renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 41 Tabla 10&#46; Tabla 11&#46; Tabla 12&#46; Tabla 13&#46; Tabla 14&#46; Tabla 15&#46; Tabla 16&#46; Tabla 17&#46; Tabla 18&#46; Tabla 19&#46; 5 &#205;NDICE DE TABLAS Tabla 20&#46; Tabla 21&#46; Tabla 22&#46; Tabla 23&#46; Tabla 24&#46; Tabla 25&#46; Estudios de correlaci&#243;n de proteinuria de 24 horas con el cociente prote&#237;nas&#47;creatinina en una muestra aislada de orina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 42 Estudios de correlaci&#243;n de albuminuria de 24 horas con cociente alb&#250;mina&#47;creatinina en una muestra aislada de orina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 42 Definiciones de microalbuminuria y macroalbuminuria &#40;proteinuria&#41; seg&#250;n la excreci&#243;n urinaria de alb&#250;mina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 43 Control peri&#243;dico de albuminuria y proteinuria en pacientes con enfermedad renal cr&#243;nica o con factores de riesgo de enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 44 Principales factores de riesgo cardiovascular seg&#250;n el informe JNC-7&#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 47 Datos de afectaci&#243;n renal en la valoraci&#243;n del paciente y en la estratificaci&#243;n del riesgo cardiovascular seg&#250;n las distintas gu&#237;as sobre el manejo de la hipertensi&#243;n arterial &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 50 Principales estudios sobre la insuficiencia renal como factor de riesgo cardiovascular y de muerte en poblaci&#243;n general &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 51 Principales estudios sobre la insuficiencia renal como factor de riesgo cardiovascular y de muerte en pacientes con hipertensi&#243;n arterial &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 53 Principales estudios sobre la insuficiencia renal como factor de riesgo en pacientes con enfermedad vascular establecida &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 55 Principales estudios sobre la microalbuminuria y proteinuria como factor de riesgo cardiovascular y de muerte en pacientes con diabetes tipo 2 &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 58 Principales estudios sobre la microalbuminuria y proteinuria como factores de riesgo cardiovascular y de muerte en pacientes no diab&#233;ticos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 59 Factores y marcadores de riesgo cardiovascular&#58; objetivos y tratamiento &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 63 Factores de riesgo de desarrollo de hipertrofia de ventr&#237;culo izquierdo y su tratamiento &#46; &#46; &#46; &#46; &#46; 67 Objetivos del tratamiento de la fibrilaci&#243;n auricular en pacientes con insuficiencia renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 68 Medidas para detecci&#243;n y control del tabaquismo en pacientes con insuficiencia renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 68 Enfermedad renal vascular o nefropat&#237;a vascular&#58; entidades englobadas &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 75 Diagn&#243;stico diferencial entre nefroangioesclerosis y otras enfermedades renales &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 75 Datos de sospecha de nefropat&#237;a isqu&#233;mica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 75 Principales estudios sobre el efecto de la HTA en la funci&#243;n renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 77 Diferencias entre pacientes hipertensos con o sin da&#241;o renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 78 Pruebas diagn&#243;sticas no invasivas para el estudio de la nefropat&#237;a isqu&#233;mica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 80 Tabla 26&#46; Tabla 27&#46; Tabla 28&#46; Tabla 29&#46; Tabla 30&#46; Tabla 31&#46; Tabla 32&#46; Tabla 33&#46; Tabla 34&#46; Tabla 35&#46; Tabla 36&#46; Tabla 37&#46; Tabla 38&#46; Tabla 39&#46; Tabla 40&#46; 6 &#205;NDICE DE TABLAS Tabla 41&#46; Tabla 42&#46; Tabla 43&#46; Tabla 44&#46; Tabla 45&#46; Tabla 46&#46; Tabla 47&#46; Tabla 48&#46; Tabla 49&#46; Tabla 50&#46; Tabla 51&#46; Principales estudios aleatorizados sobre el manejo de la enfermedad renovascular ateroscler&#243;tica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 80 Posibles indicaciones de tratamiento intervencionista y limitaciones en el manejo de la enfermedad renovascular ateroescler&#243;tica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 82 Objetivos terap&#233;uticos en cada uno de los estadios de la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 88 Factores que influyen en la progresi&#243;n de la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 88 Recomendaciones para la derivaci&#243;n al nefr&#243;logo de pacientes con diabetes mellitus &#46; &#46; &#46; &#46; &#46; &#46; 89 Renoprotecci&#243;n&#58; estrategia terap&#233;utica global &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 90 Objetivos para la nefroprotecci&#243;n y la prevenci&#243;n cardiovascular en el paciente con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 91 Medidas de nefroprotecci&#243;n y prevenci&#243;n cardiovascular en el paciente con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 92 Principales estudios sobre protecci&#243;n renal mediante tratamiento con IECA &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 95 Principales estudios sobre protecci&#243;n renal mediante tratamiento con ARAII &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 95 Definiciones de enfermedad renal&#44; indicaciones farmacol&#243;gicas establecidas y posibles y objetivos de control en las principales gu&#237;as sobre el manejo de la hipertensi&#243;n arterial &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 96 Indicaciones preferentes de f&#225;rmacos antihipertensivos en la enfermedad renal cr&#243;nica y objetivos de control seg&#250;n la gu&#237;a K&#47;DOQI 2004 sobre hipertensi&#243;n y f&#225;rmacos antihipertensivos en la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 98 Indicaciones y contraindicaciones de f&#225;rmacos diur&#233;ticos&#44; betabloqueantes&#44; calcioantagonistas y alfabloqueantes &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 98 F&#225;rmacos antihipertensivos&#58; rangos e intervalos de dosis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 99 Efectos secundarios espec&#237;ficos de clase de los f&#225;rmacos antihipertensivos&#46; Precauciones &#46; &#46; 100 Precauciones en el uso de f&#225;rmacos IECA&#44; ARAII o diur&#233;ticos en pacientes con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 100 Evidencias sobre el efecto nefroprotector de IECA y ARA II &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 101 Bloqueo del sistema renina-angiotensina con IECA en pacientes con diabetes mellitus &#46; &#46; &#46; &#46; &#46; 103 Bloqueo del sistema renina-angiotensina con IECA en pacientes con nefropat&#237;a no diab&#233;tica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 104 Estudios comparativos de IECA frente a otros f&#225;rmacos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 106 Meta-an&#225;lisis comparativos de IECA frente a otros f&#225;rmacos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 107 Bloqueo del sistema renina-angiotensina con ARAII en pacientes con diabetes mellitus &#46; &#46; &#46; &#46; 108 Tabla 52&#46; Tabla 53&#46; Tabla 54&#46; Tabla 55&#46; Tabla 56&#46; Tabla 57&#46; Tabla 58&#46; Tabla 59&#46; Tabla 60&#46; Tabla 61&#46; Tabla 62&#46; 7 &#205;NDICE DE TABLAS Tabla 63&#46; Tabla 64&#46; Tabla 65&#46; Tabla 66&#46; Tabla 67&#46; Tabla 68&#46; Tabla 69&#46; Tabla 70&#46; Tabla 71&#46; Tabla 72&#46; Tabla 73&#46; Tabla 74&#46; Tabla 75&#46; Tabla 76&#46; Tabla 77&#46; Tabla 78&#46; Tabla 79&#46; Tabla 80&#46; Tabla 81&#46; Tabla 82&#46; Tabla 83&#46; Tabla 84&#46; Tabla 85&#46; Tabla 86&#46; Bloqueo del sistema renina-angiotensina con ARA II en pacientes con nefropat&#237;a no diab&#233;tica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 109 Bloqueo combinado del sistema renina-angitensina con IECA &#43; ARAII en pacientes con diabetes mellitus &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 109 Bloqueo dual del sistema renina-angitensina con IECA &#43; ARAII en pacientes con nefropat&#237;a no diab&#233;tica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 110 Objetivos terap&#233;uticos en el tratamiento de las dislipemias en pacientes con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 113 Definiciones de dislipemia en la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 115 Dislipemia en la poblaci&#243;n general y en la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 115 Alteraciones lip&#237;dicas en la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 116 Estudios que relacionan dislipemia y progresi&#243;n de la insuficiencia renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 119 Estudios con estatinas en pacientes en hemodi&#225;lisis y di&#225;lisis peritoneal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 121 Estudios en marcha aleatorizados y controlados sobre el efecto de las estatinas en pacientes con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 122 Estudios aleatorizados con estatinas en pacientes con trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 123 Dosis de estatinas en funci&#243;n del filtrado glomerular &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 124 Cambios en los h&#225;bitos de vida en pacientes con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 125 Antiagregantes&#58; caracter&#237;sticas farmacol&#243;gicas y terap&#233;uticas &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;130 Anticoagulantes&#58; caracter&#237;sticas farmacol&#243;gicas y terap&#233;uticas &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;133 Recomendaciones para el uso de agentes antiagregantes en distintas situaciones con complicaciones vasculares &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;137 Tratamiento antiagregante&#58; principales agentes terap&#233;uticos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;138 Tratamiento anticoagulante&#58; principales agentes terap&#233;uticos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;140 Factores de riesgo cardiovascular en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;146 Hipertrofia de ventr&#237;culo izquierdo en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;148 Pacientes en di&#225;lisis que requieren estudios diagn&#243;sticos de cardiopat&#237;a isqu&#233;mica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;149 Utilidad de las pruebas diagn&#243;sticas de cardiopat&#237;a isqu&#233;mica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;149 Tratamiento m&#233;dico de la cardiopat&#237;a isqu&#233;mica en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;151 Causas de mayor prevalencia de reestenosis coronaria en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;153 8 &#205;NDICE DE TABLAS Tabla 87&#46; Tabla 88&#46; Tabla 89&#46; Tabla 90&#46; Tabla 91&#46; Tabla 92&#46; Tabla 93&#46; Tabla 94&#46; Tabla 95&#46; Tabla 96&#46; Tabla 97&#46; Tabla 98&#46; Tabla 99&#46; Revascularizaci&#243;n coronaria de pacientes en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;153 Factores asociados con calcificaciones vasculares en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;154 M&#233;todos diagn&#243;sticos de calcificaciones vasculares &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;155 Prevalencia aumentada de ictus en di&#225;lisis&#58; factores relacionados &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;159 Fibrilaci&#243;n auricular&#46; Medidas terap&#233;uticas &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;161 Indicaciones de f&#225;rmacos antihipertensivos en diferentes situaciones cl&#237;nicas en di&#225;lisis &#46; &#46; &#46; &#46;162 Consideraciones especiales de la hipertensi&#243;n arterial en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;164 Factores implicados en la patog&#233;nesis de la hipertensi&#243;n arterial en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;164 Mecanismos implicados en la hipertensi&#243;n arterial inducida por eritropoyetina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;165 Estudios sobre relaci&#243;n entre PA en di&#225;lisis y mortalidad &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;166 Recomendaciones para el uso de f&#225;rmacos antihipertensivos en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;168 Factores de riesgo cardiovascular en el trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;172 Factores de riesgo para el desarrollo de diabetes postrasplante &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;174 Tabla 100&#46; Factores etiol&#243;gicos de la dislipemia postrasplante &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;175 Tabla 101&#46; Efecto de los inmunosupresores sobre los factores de riesgo cardiovascular &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;175 Tabla 102&#46; Causas de proteinuria postrasplante &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;175 Tabla 103&#46; Factores de riesgo en la cardiopat&#237;a isqu&#233;mica postrasplante &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;176 Tabla 104&#46; Recomendaciones para el screening coronario de pacientes en lista de espera de trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;177 Tabla 105&#46; Pruebas disponibles para el estudio de la enfermedad card&#237;aca &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;178 Tabla 106&#46; Elecci&#243;n del f&#225;rmaco antihipertensivo en el trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;180 Tabla 107&#46; Causas de hipertensi&#243;n arterial en el trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;182 Tabla 108&#46; Tratamiento de la hipertensi&#243;n arterial&#58; modificaciones del estilo de vida &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;184 Tabla 109&#46; Efectos de los antihipertensivos sobre la hemodin&#225;mica renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;185 Tabla 110&#46; Interacciones de los f&#225;rmacos antihipertensivos con el tratamiento inmunosupresor &#46; &#46; &#46; &#46; &#46; &#46; &#46;186 Tabla 111&#46; Estudios sobre retirada de esteroides en el trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;186 Tabla 112&#46; Estudios sobre retirada de ciclosporina A en el trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;186 9 "
    "pdfFichero" => "P7-E237-S140-A3095.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "es"
  "url" => "/02116995/00000024000000S6/v0_201502091332/X0211699504030713/v0_201502091332/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S6/v0_201502091332/X0211699504030713/v0_201502091332/es/P7-E237-S140-A3095.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504030713?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Indice de tablas
Sociedad Española de Nefrología
Leído
9853
Veces
se ha leído el artículo
2613
Total PDF
7240
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699504030713"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2004-12-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2004;24 Supl 6:5-9"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 4433
    "formatos" => array:3 [
      "EPUB" => 298
      "HTML" => 3410
      "PDF" => 725
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699504030705"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-12-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 6:10-1"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4487
      "formatos" => array:3 [
        "EPUB" => 309
        "HTML" => 3593
        "PDF" => 585
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Indice de figuras y algoritmos"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "10"
          "paginaFinal" => "11"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504030705?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S6/v0_201502091332/X0211699504030705/v0_201502091332/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699504030721"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2004-12-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2004;24 Supl 6:0"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3814
      "formatos" => array:3 [
        "EPUB" => 283
        "HTML" => 2777
        "PDF" => 754
      ]
    ]
    "es" => array:9 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Indice General</span>"
      "titulo" => "Indice General"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "0"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504030721?idApp=UINPBA000064"
    "url" => "/02116995/00000024000000S6/v0_201502091332/X0211699504030721/v0_201502091332/es/main.assets"
  ]
  "es" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Indice de tablas"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "5"
        "paginaFinal" => "9"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "Sociedad Espa&#241;ola de Nefrolog&#237;a"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOG&#205;A&#46; Volumen 24&#46; Suplemento N&#186; 6 &#183; 2004 &#205;ndice de tablas Tabla 1&#46; Tabla 2&#46; Tabla 3&#46; Tabla 4&#46; Tabla 5&#46; Tabla 6&#46; Tabla 7&#46; Tabla 8&#46; Tabla 9&#46; Definici&#243;n de los niveles de evidencia &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 19 Principales mecanismos hipertensivos de origen renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 22 Factores implicados en el desarrollo de la aterosclerosis en los pacientes con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 23 Clasificaci&#243;n de los estadios de la enfermedad renal cr&#243;nica &#40;ERC&#41; seg&#250;n las gu&#237;as de la National Kidney Foundation &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 27 Plan de actuaci&#243;n en los distintos estadios de enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 28 Objetivos principales de las gu&#237;as de la National Kidney Foundation &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 30 Situaciones consideradas como da&#241;o renal para el diagn&#243;stico de enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 30 Prevalencia de enfermedad renal cr&#243;nica en la poblaci&#243;n no institucionalizada mayor de 20 a&#241;os en Estados Unidos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 31 Prevalencia de las distintas categor&#237;as de funci&#243;n renal seg&#250;n el m&#233;todo utilizado y por grupos de edad en la poblaci&#243;n no institucionalizada mayor de 20 a&#241;os en Estados Unidos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 31 Datos principales de los estudios sobre prevalencia de enfermedad renal cr&#243;nica en Espa&#241;a &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 32 Situaciones de riesgo aumentado de enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 33 Factores de riesgo para la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 33 Principales ecuaciones para la medida de la funci&#243;n renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 36 Medidas &#34;ideales&#34; de funci&#243;n renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 37 Problemas de la determinaci&#243;n de creatinina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 37 Problemas de la determinaci&#243;n del aclaramiento de creatinina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 39 Ecuaciones recomendadas para estimar la funci&#243;n renal en pacientes en situaci&#243;n estable &#46; &#46; &#46; 39 Estudios comparativos entre las ecuaciones MDRD y Cockcroft-Gault &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 40 Situaciones en las que no se recomienda la utilizaci&#243;n de ecuaciones para medir la funci&#243;n renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 41 Tabla 10&#46; Tabla 11&#46; Tabla 12&#46; Tabla 13&#46; Tabla 14&#46; Tabla 15&#46; Tabla 16&#46; Tabla 17&#46; Tabla 18&#46; Tabla 19&#46; 5 &#205;NDICE DE TABLAS Tabla 20&#46; Tabla 21&#46; Tabla 22&#46; Tabla 23&#46; Tabla 24&#46; Tabla 25&#46; Estudios de correlaci&#243;n de proteinuria de 24 horas con el cociente prote&#237;nas&#47;creatinina en una muestra aislada de orina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 42 Estudios de correlaci&#243;n de albuminuria de 24 horas con cociente alb&#250;mina&#47;creatinina en una muestra aislada de orina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 42 Definiciones de microalbuminuria y macroalbuminuria &#40;proteinuria&#41; seg&#250;n la excreci&#243;n urinaria de alb&#250;mina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 43 Control peri&#243;dico de albuminuria y proteinuria en pacientes con enfermedad renal cr&#243;nica o con factores de riesgo de enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 44 Principales factores de riesgo cardiovascular seg&#250;n el informe JNC-7&#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 47 Datos de afectaci&#243;n renal en la valoraci&#243;n del paciente y en la estratificaci&#243;n del riesgo cardiovascular seg&#250;n las distintas gu&#237;as sobre el manejo de la hipertensi&#243;n arterial &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 50 Principales estudios sobre la insuficiencia renal como factor de riesgo cardiovascular y de muerte en poblaci&#243;n general &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 51 Principales estudios sobre la insuficiencia renal como factor de riesgo cardiovascular y de muerte en pacientes con hipertensi&#243;n arterial &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 53 Principales estudios sobre la insuficiencia renal como factor de riesgo en pacientes con enfermedad vascular establecida &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 55 Principales estudios sobre la microalbuminuria y proteinuria como factor de riesgo cardiovascular y de muerte en pacientes con diabetes tipo 2 &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 58 Principales estudios sobre la microalbuminuria y proteinuria como factores de riesgo cardiovascular y de muerte en pacientes no diab&#233;ticos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 59 Factores y marcadores de riesgo cardiovascular&#58; objetivos y tratamiento &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 63 Factores de riesgo de desarrollo de hipertrofia de ventr&#237;culo izquierdo y su tratamiento &#46; &#46; &#46; &#46; &#46; 67 Objetivos del tratamiento de la fibrilaci&#243;n auricular en pacientes con insuficiencia renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 68 Medidas para detecci&#243;n y control del tabaquismo en pacientes con insuficiencia renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 68 Enfermedad renal vascular o nefropat&#237;a vascular&#58; entidades englobadas &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 75 Diagn&#243;stico diferencial entre nefroangioesclerosis y otras enfermedades renales &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 75 Datos de sospecha de nefropat&#237;a isqu&#233;mica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 75 Principales estudios sobre el efecto de la HTA en la funci&#243;n renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 77 Diferencias entre pacientes hipertensos con o sin da&#241;o renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 78 Pruebas diagn&#243;sticas no invasivas para el estudio de la nefropat&#237;a isqu&#233;mica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 80 Tabla 26&#46; Tabla 27&#46; Tabla 28&#46; Tabla 29&#46; Tabla 30&#46; Tabla 31&#46; Tabla 32&#46; Tabla 33&#46; Tabla 34&#46; Tabla 35&#46; Tabla 36&#46; Tabla 37&#46; Tabla 38&#46; Tabla 39&#46; Tabla 40&#46; 6 &#205;NDICE DE TABLAS Tabla 41&#46; Tabla 42&#46; Tabla 43&#46; Tabla 44&#46; Tabla 45&#46; Tabla 46&#46; Tabla 47&#46; Tabla 48&#46; Tabla 49&#46; Tabla 50&#46; Tabla 51&#46; Principales estudios aleatorizados sobre el manejo de la enfermedad renovascular ateroscler&#243;tica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 80 Posibles indicaciones de tratamiento intervencionista y limitaciones en el manejo de la enfermedad renovascular ateroescler&#243;tica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 82 Objetivos terap&#233;uticos en cada uno de los estadios de la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 88 Factores que influyen en la progresi&#243;n de la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 88 Recomendaciones para la derivaci&#243;n al nefr&#243;logo de pacientes con diabetes mellitus &#46; &#46; &#46; &#46; &#46; &#46; 89 Renoprotecci&#243;n&#58; estrategia terap&#233;utica global &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 90 Objetivos para la nefroprotecci&#243;n y la prevenci&#243;n cardiovascular en el paciente con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 91 Medidas de nefroprotecci&#243;n y prevenci&#243;n cardiovascular en el paciente con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 92 Principales estudios sobre protecci&#243;n renal mediante tratamiento con IECA &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 95 Principales estudios sobre protecci&#243;n renal mediante tratamiento con ARAII &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 95 Definiciones de enfermedad renal&#44; indicaciones farmacol&#243;gicas establecidas y posibles y objetivos de control en las principales gu&#237;as sobre el manejo de la hipertensi&#243;n arterial &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 96 Indicaciones preferentes de f&#225;rmacos antihipertensivos en la enfermedad renal cr&#243;nica y objetivos de control seg&#250;n la gu&#237;a K&#47;DOQI 2004 sobre hipertensi&#243;n y f&#225;rmacos antihipertensivos en la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 98 Indicaciones y contraindicaciones de f&#225;rmacos diur&#233;ticos&#44; betabloqueantes&#44; calcioantagonistas y alfabloqueantes &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 98 F&#225;rmacos antihipertensivos&#58; rangos e intervalos de dosis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 99 Efectos secundarios espec&#237;ficos de clase de los f&#225;rmacos antihipertensivos&#46; Precauciones &#46; &#46; 100 Precauciones en el uso de f&#225;rmacos IECA&#44; ARAII o diur&#233;ticos en pacientes con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 100 Evidencias sobre el efecto nefroprotector de IECA y ARA II &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 101 Bloqueo del sistema renina-angiotensina con IECA en pacientes con diabetes mellitus &#46; &#46; &#46; &#46; &#46; 103 Bloqueo del sistema renina-angiotensina con IECA en pacientes con nefropat&#237;a no diab&#233;tica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 104 Estudios comparativos de IECA frente a otros f&#225;rmacos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 106 Meta-an&#225;lisis comparativos de IECA frente a otros f&#225;rmacos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 107 Bloqueo del sistema renina-angiotensina con ARAII en pacientes con diabetes mellitus &#46; &#46; &#46; &#46; 108 Tabla 52&#46; Tabla 53&#46; Tabla 54&#46; Tabla 55&#46; Tabla 56&#46; Tabla 57&#46; Tabla 58&#46; Tabla 59&#46; Tabla 60&#46; Tabla 61&#46; Tabla 62&#46; 7 &#205;NDICE DE TABLAS Tabla 63&#46; Tabla 64&#46; Tabla 65&#46; Tabla 66&#46; Tabla 67&#46; Tabla 68&#46; Tabla 69&#46; Tabla 70&#46; Tabla 71&#46; Tabla 72&#46; Tabla 73&#46; Tabla 74&#46; Tabla 75&#46; Tabla 76&#46; Tabla 77&#46; Tabla 78&#46; Tabla 79&#46; Tabla 80&#46; Tabla 81&#46; Tabla 82&#46; Tabla 83&#46; Tabla 84&#46; Tabla 85&#46; Tabla 86&#46; Bloqueo del sistema renina-angiotensina con ARA II en pacientes con nefropat&#237;a no diab&#233;tica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 109 Bloqueo combinado del sistema renina-angitensina con IECA &#43; ARAII en pacientes con diabetes mellitus &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 109 Bloqueo dual del sistema renina-angitensina con IECA &#43; ARAII en pacientes con nefropat&#237;a no diab&#233;tica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 110 Objetivos terap&#233;uticos en el tratamiento de las dislipemias en pacientes con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 113 Definiciones de dislipemia en la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 115 Dislipemia en la poblaci&#243;n general y en la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 115 Alteraciones lip&#237;dicas en la enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 116 Estudios que relacionan dislipemia y progresi&#243;n de la insuficiencia renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 119 Estudios con estatinas en pacientes en hemodi&#225;lisis y di&#225;lisis peritoneal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 121 Estudios en marcha aleatorizados y controlados sobre el efecto de las estatinas en pacientes con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 122 Estudios aleatorizados con estatinas en pacientes con trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 123 Dosis de estatinas en funci&#243;n del filtrado glomerular &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 124 Cambios en los h&#225;bitos de vida en pacientes con enfermedad renal cr&#243;nica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; 125 Antiagregantes&#58; caracter&#237;sticas farmacol&#243;gicas y terap&#233;uticas &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;130 Anticoagulantes&#58; caracter&#237;sticas farmacol&#243;gicas y terap&#233;uticas &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;133 Recomendaciones para el uso de agentes antiagregantes en distintas situaciones con complicaciones vasculares &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;137 Tratamiento antiagregante&#58; principales agentes terap&#233;uticos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;138 Tratamiento anticoagulante&#58; principales agentes terap&#233;uticos &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;140 Factores de riesgo cardiovascular en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;146 Hipertrofia de ventr&#237;culo izquierdo en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;148 Pacientes en di&#225;lisis que requieren estudios diagn&#243;sticos de cardiopat&#237;a isqu&#233;mica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;149 Utilidad de las pruebas diagn&#243;sticas de cardiopat&#237;a isqu&#233;mica &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;149 Tratamiento m&#233;dico de la cardiopat&#237;a isqu&#233;mica en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;151 Causas de mayor prevalencia de reestenosis coronaria en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;153 8 &#205;NDICE DE TABLAS Tabla 87&#46; Tabla 88&#46; Tabla 89&#46; Tabla 90&#46; Tabla 91&#46; Tabla 92&#46; Tabla 93&#46; Tabla 94&#46; Tabla 95&#46; Tabla 96&#46; Tabla 97&#46; Tabla 98&#46; Tabla 99&#46; Revascularizaci&#243;n coronaria de pacientes en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;153 Factores asociados con calcificaciones vasculares en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;154 M&#233;todos diagn&#243;sticos de calcificaciones vasculares &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;155 Prevalencia aumentada de ictus en di&#225;lisis&#58; factores relacionados &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;159 Fibrilaci&#243;n auricular&#46; Medidas terap&#233;uticas &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;161 Indicaciones de f&#225;rmacos antihipertensivos en diferentes situaciones cl&#237;nicas en di&#225;lisis &#46; &#46; &#46; &#46;162 Consideraciones especiales de la hipertensi&#243;n arterial en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;164 Factores implicados en la patog&#233;nesis de la hipertensi&#243;n arterial en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;164 Mecanismos implicados en la hipertensi&#243;n arterial inducida por eritropoyetina &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;165 Estudios sobre relaci&#243;n entre PA en di&#225;lisis y mortalidad &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;166 Recomendaciones para el uso de f&#225;rmacos antihipertensivos en di&#225;lisis &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;168 Factores de riesgo cardiovascular en el trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;172 Factores de riesgo para el desarrollo de diabetes postrasplante &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;174 Tabla 100&#46; Factores etiol&#243;gicos de la dislipemia postrasplante &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;175 Tabla 101&#46; Efecto de los inmunosupresores sobre los factores de riesgo cardiovascular &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;175 Tabla 102&#46; Causas de proteinuria postrasplante &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;175 Tabla 103&#46; Factores de riesgo en la cardiopat&#237;a isqu&#233;mica postrasplante &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;176 Tabla 104&#46; Recomendaciones para el screening coronario de pacientes en lista de espera de trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;177 Tabla 105&#46; Pruebas disponibles para el estudio de la enfermedad card&#237;aca &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;178 Tabla 106&#46; Elecci&#243;n del f&#225;rmaco antihipertensivo en el trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;180 Tabla 107&#46; Causas de hipertensi&#243;n arterial en el trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;182 Tabla 108&#46; Tratamiento de la hipertensi&#243;n arterial&#58; modificaciones del estilo de vida &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;184 Tabla 109&#46; Efectos de los antihipertensivos sobre la hemodin&#225;mica renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;185 Tabla 110&#46; Interacciones de los f&#225;rmacos antihipertensivos con el tratamiento inmunosupresor &#46; &#46; &#46; &#46; &#46; &#46; &#46;186 Tabla 111&#46; Estudios sobre retirada de esteroides en el trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;186 Tabla 112&#46; Estudios sobre retirada de ciclosporina A en el trasplante renal &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46; &#46;186 9 "
    "pdfFichero" => "P7-E237-S140-A3095.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "es"
  "url" => "/02116995/00000024000000S6/v0_201502091332/X0211699504030713/v0_201502091332/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000024000000S6/v0_201502091332/X0211699504030713/v0_201502091332/es/P7-E237-S140-A3095.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699504030713?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Español
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 12 13 25
2024 Octubre 105 45 150
2024 Septiembre 69 23 92
2024 Agosto 63 64 127
2024 Julio 71 30 101
2024 Junio 88 44 132
2024 Mayo 86 51 137
2024 Abril 85 32 117
2024 Marzo 61 30 91
2024 Febrero 69 42 111
2024 Enero 56 22 78
2023 Diciembre 54 29 83
2023 Noviembre 60 31 91
2023 Octubre 59 30 89
2023 Septiembre 54 29 83
2023 Agosto 56 27 83
2023 Julio 92 36 128
2023 Junio 120 27 147
2023 Mayo 81 32 113
2023 Abril 56 23 79
2023 Marzo 67 30 97
2023 Febrero 51 24 75
2023 Enero 59 35 94
2022 Diciembre 51 36 87
2022 Noviembre 72 32 104
2022 Octubre 73 46 119
2022 Septiembre 83 26 109
2022 Agosto 69 42 111
2022 Julio 73 47 120
2022 Junio 49 43 92
2022 Mayo 53 27 80
2022 Abril 76 56 132
2022 Marzo 64 49 113
2022 Febrero 46 41 87
2022 Enero 55 41 96
2021 Diciembre 50 44 94
2021 Noviembre 66 38 104
2021 Octubre 85 48 133
2021 Septiembre 69 39 108
2021 Agosto 47 50 97
2021 Julio 62 40 102
2021 Junio 59 29 88
2021 Mayo 63 34 97
2021 Abril 153 35 188
2021 Marzo 63 45 108
2021 Febrero 78 22 100
2021 Enero 60 24 84
2020 Diciembre 50 20 70
2020 Noviembre 57 11 68
2020 Octubre 57 17 74
2020 Septiembre 52 33 85
2020 Agosto 52 22 74
2020 Julio 46 20 66
2020 Junio 59 15 74
2020 Mayo 77 25 102
2020 Abril 66 18 84
2020 Marzo 86 15 101
2020 Febrero 70 19 89
2020 Enero 63 31 94
2019 Diciembre 52 20 72
2019 Noviembre 55 13 68
2019 Octubre 46 22 68
2019 Septiembre 72 17 89
2019 Agosto 46 17 63
2019 Julio 59 27 86
2019 Junio 64 25 89
2019 Mayo 66 20 86
2019 Abril 96 47 143
2019 Marzo 90 25 115
2019 Febrero 50 25 75
2019 Enero 45 24 69
2018 Diciembre 83 32 115
2018 Noviembre 112 21 133
2018 Octubre 71 22 93
2018 Septiembre 87 13 100
2018 Agosto 77 8 85
2018 Julio 49 9 58
2018 Junio 52 13 65
2018 Mayo 88 10 98
2018 Abril 91 14 105
2018 Marzo 72 12 84
2018 Febrero 64 13 77
2018 Enero 51 10 61
2017 Diciembre 68 8 76
2017 Noviembre 48 19 67
2017 Octubre 51 11 62
2017 Septiembre 44 17 61
2017 Agosto 46 16 62
2017 Julio 30 9 39
2017 Junio 47 13 60
2017 Mayo 48 21 69
2017 Abril 42 13 55
2017 Marzo 54 21 75
2017 Febrero 40 13 53
2017 Enero 34 10 44
2016 Diciembre 34 13 47
2016 Noviembre 35 13 48
2016 Octubre 37 12 49
2016 Septiembre 112 8 120
2016 Agosto 98 2 100
2016 Julio 114 6 120
2016 Junio 66 0 66
2016 Mayo 107 0 107
2016 Abril 42 0 42
2016 Marzo 54 0 54
2016 Febrero 58 0 58
2016 Enero 45 0 45
2015 Diciembre 50 0 50
2015 Noviembre 57 0 57
2015 Octubre 43 0 43
2015 Septiembre 33 0 33
2015 Agosto 32 0 32
2015 Julio 47 0 47
2015 Junio 21 0 21
2015 Mayo 31 0 31
2015 Abril 6 0 6
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?